Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line
treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second …

Precision oncology is the ultimate goal of cancer treatment, ie, to treat cancer and only
cancer, leaving all the remaining cells and tissues as intact as possible. Classical …

Several studies have shown that metallic nanoparticles have a therapeutic impact on
leukemia cells. On the other hand, the majority of these particles are hazardous to healthy …

Antimicrobial peptides derived from the skin secretions of amphibians have made important
progress in tumor therapy due to their unique mechanism of destroying cell membranes …

Venetoclax is a BCL2-targeted drug employed in treating various cancers, particularly
hematologic malignancies. Venetoclax combination therapies are increasingly recognized …

Modern clinical therapy of chronic myeloid leukemia (CML) with TKIs is highly efficacious in
most CML patients, while it is not remedial and generally confined due to intolerance or …

Chronic myeloid leukaemia (CML) is caused by BCR:: ABL1. Tyrosine kinase-inhibitors
(TKIs) are the initial therapy. Several organizations have reported milestones to evaluate …

Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and
the overall survival of resistant patients in the chronic phase who changed a second …

Chronic myeloid leukemia (CML) is a common adult leukemia. Both the acute phase of the
disease and the adverse effects of anti-cancer treatments can lead to a poor prognosis. The …

Myeloid leukemia is a chronic cancer, which associated with abnormal BCR-ABL tyrosine
kinase activity. Imatinib (IMB) acts as a tyrosine kinase inhibitor and averts tumor growth in …